A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Cancer, Metastatic Cancer, Breast Cancer

In brief

This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib * Learn more about the side effects of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with niraparib

Key facts

Study ID

NCT04991480

Run by

Artios Pharma Ltd

People needed

93

Starts

2021-09-13

Expected to finish

2025-12-24

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Yale School of Medicine — New Haven, Connecticut, United States
• Florida Cancer Specialists — Orlando, Florida, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Oklahoma University — Oklahoma City, Oklahoma, United States
• University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Sarah Cannon Research Institute — London, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.